ALung is now proud to be part of LivaNova.

Currently, the HEMOLUNG does not have a Medicare MS-DRG Assignment Code. It will be included as part of the following MS-DRGs until a new MS-DRG is created and assigned.

MS-DRG

Description

207

RESPIRATORY SYSTEM DIAGNOSIS WITH VENTILATOR SUPPORT >96 HOURS OR PERIPHERAL EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)

208

RESPIRATORY SYSTEM DIAGNOSIS W VENTILATOR SUPPORT<=96 HOURS

The HEMOLUNG is indicated for respiratory support that provides extracorporeal carbon dioxide (CO2) removal from the patient’s blood for up to 5 days in adults with acute, reversible respiratory failure for whom ventilation of CO2 cannot be adequately or safely achieved using other available treatment options and continued clinical deterioration is expected.

This indication provides a means to assist in ventilator support as part of MS-DRGs 207 and 208. At this time, no additional reimbursement is available for the use of the HEMOLUNG.

New Technology Add-on Payment (NTAP) CMS Program

The Hemolung was recently approved for a New Technology Add-On Payment (NTAP) by the Medicare hospital inpatient prospective payments (IPPS). NTAPs allow for more appropriate reimbursement for new medical services and technology not yet included in Diagnosis Related Group (DRG) rates.

The Hemolung NTAP will go into effect on October 1, 2022. For additional information, please e-mail info@alung.com.